Market Approval for Bioperfectus COVID-19 Self-test in Portugal

Company news
2022-02-09

As a manufacturer of infectious disease in-vitro diagnostic products, Bioperfectus gained another market approval for Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test) in Portugal. This is another recognition of our COVID-19 Self-test products in EU countries.

 

Como fabricante de produtos de diagnóstico in vitro de doenças infecciosas, a Bioperfectus obteve outra aprovação de mercado para o Novel Corona Virus (SARS-CoV-2) Ag Rapid Test Kit (Self-test) em Portugal. Este é mais um reconhecimento dos nossos produtos de autoteste de COVID-19 nos países da UE.

To learn more, visit www.bioperfectus.com or send an email to info@bioperfectus.com.

 

Para saber mais, visite www.bioperfectus.com ou envie um e-mail para info@bioperfectus.com.

MOST READ

Bioperfectus Supports Cholera Elimination

SHANGHAI, CHINA, December 5, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”) is pleased to launch Vibrio Cholerae Real Time PCR Kits for human diagnosis and early warning surveillance.

2022-11-30

Client Story: A Race Against Time

Through a critical assessment of clinical evaluation and data validation, Bioperfetus successfully passed the Israeli ministry of health inspection. Bioperfetus was the only Chinese company on the procurement list and was asked to provide one million antigen rapid test kits for the Israeli ministry of health.

2022-11-15

Bioperfectus Granted MDA Approval in Malaysia for Nucleic Acid Extraction Systems

SHANGHAI, CHINA, November 14, 2022—Jiangsu Bioperfectus Technologies Co., Ltd. (hereinafter referred to as “Bioperfectus”), a leading global company in the molecular diagnostics market, today announced receipt of MDA (Medical Device Authority) approval in Malaysia for Nucleic Acid Extraction Systems, including Nucleic Acid SSNP-2000B, SSNP-3000A, SSNP-9600A, SMPE-960 and Extraction Rapid Kit (Magnetic Bead Method).

2022-11-14